Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iStent Inject with Travoprost in Open-angle Glaucoma
NCT02873806Phase 4Completed
- Sponsor
- Glaukos Corporation
- Start
- Mar 2013
- Primary completion
- Nov 2019
- Countries
- 1
01
Overview
Phase 4, single-blind, single-arm trial, sponsored by Glaukos Corporation. Primary endpoint: Mean intraocular pressure reduction of 20% or more versus baseline with reduction of 1 medication at 12 months. Started Mar 2013; status: completed.
Beyond the preview
Go deeper on NCT02873806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873806.